Background
Coincidence imaging of low-abundance yttrium-90 ( 90 Y) internal pair production by 90 Y positron emission tomography with integrated computed tomography (PET/CT) achieves high-resolution imaging of post-radioembolization microsphere biodistribution. In part 1, we reviewed the recent literature supporting the use of post-radioembolization 90 Y PET/CT, described our scan protocol, patient cohort, diagnostic reporting guidelines, and results of qualitative analysis [1] . In brief, we showed that with proper diagnostic reporting technique and emphasis on continuity of care, the presence of background noise did not pose a problem and 90 Y PET/CT consistently out-performed 90 Y bremsstrahlung single-photon emission computed tomography with integrated CT (SPECT/CT) in all aspects of qualitative analysis [1] .
The terms 'predictive dosimetry' , 'target' , 'non-target' , 'technical success' , and the 'planning-therapy continuum' were also defined in part 1 [1] . It is important for the understanding of part 2 to reiterate that our definition of technical success, an adaptation from conventional reporting standards [2] , refers to the qualitative assessment of a satisfactory 90 Y activity biodistribution in accordance with radiation planning expectations and should not be confused with 'clinical success' [2] which is quantitatively related to dose-response radiobiology.
A knowledge gap exists today between institutions which practice predictive dosimetry and others which rely on semi-empirical methods [3] . Readers who are accustomed to semi-empirical therapy planning may struggle to understand the dosimetric concepts discussed in this paper or its relevance to clinical practice. These readers are encouraged to refer to our recent series of publications explaining concepts in modern predictive dosimetry for 90 Y resin microspheres and common misconceptions [3] [4] [5] [6] .
Where prognostication is of concern, qualitative analysis alone will not suffice [3] . The scientific language of dose-response radiobiology is the radiation absorbed dose expressed in grays (Gy), not the prescribed activity expressed in becquerels (Bq). To realize the full potential of post-radioembolization 90 Y PET/CT, absorbed dose quantification should be performed in relevant clinical settings. As 90 Y radioembolization is a brachytherapy delivered by β − -emitting microspheres, any tissue response is expected to follow predictable dose-response radiobiology. In principle, accurate knowledge of radiation thresholds in both target and non-target tissue facilitates the optimization of predictive dosimetry and enables the prognostication of technically unsuccessful cases to guide adjuvant therapy or mitigative action to minimize non-target radiation toxicity.
However, accurate tissue radiation thresholds for 90 Y resin microspheres have remained elusive despite more than two decades of clinical use. Current radiation planning limits are broad and quote mean absorbed doses which falsely assume a uniform dose distribution: tumor > 120 Gy, non-tumorous liver < 50 to 70 Gy, lungs < 20 to 30 Gy [7] [8] [9] . As a consequence of this uncertainty, dosimetric dilemmas may be encountered in patients who may benefit from radiation planning up to the limits of normal tissue radiation tolerance. Furthermore, normal tissue radiation thresholds for 90 Y resin microspheres shunted to non-target viscera such as the stomach or duodenum are largely unknown, precluding informed decision making for appropriate mitigative action. Historically, research into dose-response data had been technically challenging: intraoperative beta probes or histological examinations are invasive [10, 11] , quantification by 90 Y bremsstrahlung scintigraphy is problematic and largely inaccurate [1] , and predictive dosimetry simulated by 99m Tc macroaggregated albumin (MAA) is subject to variable accuracy due to the physical limitations of MAA [12] .
Dosimetric studies have shown 99m Tc MAA to be feasible for simulating the post-radioembolization biodistribution of 90 Y resin microspheres [13] [14] [15] [16] . However, 99m Tc MAA is an imperfect surrogate for 90 Y resin microspheres. Due to biophysical and technical differences such as particle size, specific gravity, injected particle load, microembolization, and catheter placement, 99m Tc MAA can never exactly replicate the post-radioembolization biodistribution of 90 Y resin microspheres [12, 17] . Therefore, predictive dosimetry simulated by 99m Tc MAA provides only an estimate of the tissue absorbed doses intended by the nuclear medicine physician [6] . Traditionally based on planar scintigraphy [13, 14] , modern predictive dosimetry employs SPECT/ CT to tomographically assess the biodistribution of 99m Tc MAA and to improve its quantitative accuracy [6] . So far, the accuracy of 99m Tc MAA SPECT/CT predictive dosimetry has only been indirectly validated by inference from follow-up response [6, 18, 19] 
Methods

Phantom quantification
An institutional review board approval was obtained for the conduct and publication of this retrospective report (CIRB 2010/781/C, SingHealth, Singapore). Verbal consent was obtained from patients for scans to be performed. Quantitative phantom studies were first performed to confirm detector linearity of our time-of-flight lutetium-yttrium-oxyorthosilicate (LYSO) system and for comparison with a radiopharmacy dose calibrator. 90 Y resin microspheres (SIR-Spheres, Sirtex Medical Limited, North Sydney, Australia) were used. We scanned the microsphere sediment and not its fresh suspension to avoid issues with microsphere sedimentation during PET acquisition. In effect, each vial sediment represents a small heterogeneous volume of high 90 Y radioconcentration, simulating a small tumor implanted with a high and heterogeneous density of 90 Y resin microspheres. All microsphere sediments were scanned within its original glass shipping vial for convenience and to avoid operator radiation exposure for microsphere extraction.
Vials of microspheres were obtained by convenience sampling, either before or after extraction of the desired treatment activity. Phantom scans of high activities (>3.0 GBq) were performed on fresh vials on the day it was received from the manufacturer, while scans of very low activities (<0.1 GBq) were performed after a period of decay of residual vial activities. The vials were placed within a perspex body phantom and scanned in one bed position over 15 min (Figure 1 ). All scan parameters were identical to our clinical scan protocol described in part 1 [1] .
For vial activity quantification, a volume of interest (VOI) encompassing the entire vial sediment was generated by selecting a fixed volumetric isocontour threshold of 1%. The total 90 Y activity (kBq) within the VOI was calculated as the product of its mean radioconcentration (kBq/ml) and its volume (cm 3 ). Each vial sediment quantified by 90 Y PET was compared to that measured by a dose calibrator (Biodex Atomlab 500, Biodex Medical Systems, New York, NY, USA). Its purpose was to evaluate the general relative accuracy of 90 Y PET quantification in the absence of a true reference standard and also to empirically assess quantitative effects from background noise, variable vial sediment volume, radioconcentration, vial geometry, or positron contributions from possible radionuclidic impurities such as yttrium-88 [23] .
Tissue quantification
Retrospective absorbed dose quantification by 90 Y PET was performed on the same 23-patient data set as was reported in part 1 [1] . The two objectives were, first, to establish dose-response observations in tumor and nontarget tissue and, second, to evaluate the accuracy of tumor 99m Tc MAA SPECT/CT predictive dosimetry [6] in direct Gy-to-Gy comparison to post-radioembolization doses by 90 Y PET. Tumors were analyzed using cumulative 90 Y DVHs generated by voxel dosimetry. This was performed on a small select group of tumors treated under highly favorable, near-ideal dosimetric conditions to ensure reliable dose-response observations and to assess the best possible accuracy of tumor 99m Tc MAA SPECT/CT predictive dosimetry. The tumor selection criteria were as follows: technically successful 90 Y radioembolization, well-circumscribed tumors with good overall activity coverage, mean tumor-to-normal liver (T/N) ratio ≥2 as estimated by 99m Tc MAA SPECT/CT, and follow-up diagnostic sectional imaging available for clinical correlation. All tumor VOIs were manually contoured slice by slice according to CT anatomical margins. We avoided using tumor VOIs generated by PET volumetric isocontour thresholding as these often do not represent their true anatomical extent due to heterogeneous microsphere biodistribution. Regions of absent 90 Y activity in tumors were visually correlated to CT findings and excluded from VOI analysis if necrotic.
90 Y PET voxel dosimetry was performed by a novel program written in Interactive Data Language (IDL 6.1), freely available from the corresponding author for research purposes [24] . This program was initially developed for total glycolytic volume analysis of 18 Ffluorodeoxyglucose PET data [25] . The dosimetry assumes no post-implantation redistribution of microspheres, leaching, nor destruction of microspheres in vivo. Dose distribution heterogeneity was limited to the size of the reconstructed voxels; true dose heterogeneity at the microscopic level was not assessed.
Mean absorbed doses in tumor vascular thrombosis and gastric and duodenal walls were estimated by 90 Y MIRD macrodosimetry [7, 22] . For these small or thinwalled structures, 90 Y DVH analysis was not feasible due to partial volume effect and uncertainties in manual VOI delineation on CT. These issues especially affect hollow viscus, such as the stomach and duodenum, as variable wall distension or compression introduces further uncertainties in manual VOI delineation. Instead, we chose to generate VOIs by PET volumetric isocontour thresholding, visually constrained to CT anatomical margins. This obtains the mean VOI radioconcentration, from which the VOI-specific mean absorbed doses were approximated by MIRD formularism. Dose-response analysis was strictly limited to observations within these VOIs.
All tissue absorbed doses were decay-corrected back to the time of 90 Y radioembolization. Tumor response was reported using the lesion-specific modified Response Evaluation Criteria in Solid Tumors [28] . In addition, we defined a 'minor response' as any tumor size reduction which does not fulfill the criteria for a partial response. As there is no current standard for 90 Y DVH reporting, we selected the D 70 and V 100 values for tumor reporting, where D 70 represents the minimum absorbed dose This scan shows our lowest tested vial sediment activity of 3.5 MBq (≈3 MBq/ml). The upper PET visual display threshold of this scan was adjusted to 114% (2,000 kBq/ml) to minimize visual interference from background noise [1] . (d) Maximum intensity projection image of the same phantom scan (arrow indicates vial sediment) with the upper PET visual display threshold adjusted to 1% (20 kBq/ml) to reveal the underlying background noise as an example to readers [1] .
delivered to 70% of the tumor volume, and V 100 represents the percentage tumor volume receiving ≥100 Gy. Non-target absorbed doses were expressed in accordance to external beam radiotherapy convention as far as possible [29, 30] . Cases of non-target activity were followed up by retrospective review of clinical records, and relevant clinical toxicities were graded according to the Common Terminology Criteria for Adverse Events version 4.03 (CTCAE; National Institutes of Health, Bethesda, MD, USA).
The second objective of retrospective absorbed dose quantification was to evaluate the accuracy of tumor predictive dosimetry simulated by 99m Tc MAA SPECT/ CT. This was performed by a direct, i.e., Gy-to-Gy, comparison between intended tumor mean doses and postradioembolization tumor mean doses by 90 Y PET, expressed as relative percentage errors. Our protocol for predictive dosimetry was previously described [6] , which involves catheter-directed CT angiography for arterial territory delineation, quantitative 99m Tc MAA SPECT/ CT of the target organ, and MIRD macrodosimetry to achieve artery-specific personalized radiation planning for 90 Y resin microspheres.
Statistical analysis
Data are presented as median, mean, range, and 95% confidence intervals (CI), where applicable. Linear regression with Pearson's correlation coefficient (r) and
Bland-Altman plots with intraclass correlation coefficients (ICC) were used for comparison of quantitative data; a value of ≥0.8 indicated excellent correlation.
Results
Phantom validation
A total of 15 phantom scans were performed. Nearperfect detector linearity was demonstrated on our timeof-flight LYSO system within the tested limits of 3.5 MBq to 3.2 GBq (r = 0.99, calibration factor 0.99, Figure 2 ). Detector saturation was not a problem without 90 Y bremsstrahlung shielding. The Bland-Altman plot showed excellent agreement between 90 Y PET and dose calibrator measurements (ICC = 99.85%; Additional file 1: Figure S1 ).
Across all data points, the median relative quantification error of 90 Y PET was +1.38% (mean +2.18%, 95% CI −3.92% to +8.28%). Vial activities >400 MBq had very low relative quantification errors (mean +0.29%, median +0.72%, 95% CI −3.30% to +3.87%), whereas vial activities <400 MBq had larger errors (mean +4.35%, median +4.95%, 95% CI −8.43% to +17.12%; Additional file 1: Figure S2 ) -a finding attributable to background noise from 176 Lu within the LYSO crystal [31, 32] . Based on these results, we deemed it feasible to assume all tumor activities quantified by 90 Y PET to have negligible error for the purposes of this study. 
Y dose-response
Twenty-three post-radioembolization 90 Y PET/CT scans were eligible for dose-response analysis, as was reported in part 1 [1] . As per our institutional protocol, the catheter tip for 90 Y resin microsphere injection was placed in exactly the same position as for 99m Tc MAA injection in all cases, as visually assessed by the procedural interventional radiologist during 90 Table 2 .
All dose-response results of non-target tissue were serendipitously obtained in cases of unintended nontarget shunting of 90 Y resin microspheres due to unexpected vascular stasis and microsphere reflux during 90 Y radioembolization. The dose-response of the stomach ( Figure 7 ) and proximal duodenum by 90 Y MIRD macrodosimetry are presented in Table 3 .
90 Y DVH doseresponse of the right kidney is presented in Table 4 . All results were in keeping with published experiences of external beam radiotherapy [29, 30] .
Accuracy of tumor predictive dosimetry
Within the statistical limitations of our small data set of HCCs treated under near-ideal dosimetric conditions, the Bland-Altman plot of intended tumor mean doses versus post-radioembolization doses by 90 Y PET showed excellent correlation (ICC = 97.68%; Additional file 1: Figure S3 ). Tumor 99m Tc MAA SPECT/CT predictive dosimetry had a low median relative error of +3.8% (mean +6.0%, 95% CI −1.2% to +13.2%; Additional file 1: Figure S4 ) compared to 90 Y PET. There may be a tendency for tumor predictive dosimetry to slightly overestimate the post-radioembolization tumor mean dose. There was no correlation between relative errors and [36] . For example, our data suggest that HCC tumor outcomes may be optimized by escalating the injected 90 Y activity to achieve an intended tumor dose of D 70 > 100 Gy simulated by 99m Tc MAA SPECT/CT DVH, within safety limitations to the lungs and non-tumorous liver.
For non-target activity, we observed that a mean absorbed dose of 18 Gy to the stomach was asymptomatic, while ≥49 Gy to the stomach or duodenum led to CTCAE grade 3 toxicity. Quantification of nontarget absorbed doses by 90 Y PET effectively translates Subject to partial volume effect and excluded from cross-analysis in Figure 5 .
subjective, qualitative information into objective and radiobiologically meaningful data to guide postradioembolization care. This may involve close follow-up, extended use of proton pump inhibitors, surveillance endoscopy, or a trial of radioprotecting agents. For the kidney, we observed that a combined bilateral mean dose of 9 Gy (V 20 8%) did not result in any clinically relevant nephrotoxicity. This finding has clinical implications for the planning of safe kidney-directed 90 Y radioembolization for renal malignancies [37, 38] . We were unable to define In this retrospective report, we have shown tumor 99m Tc MAA SPECT/CT predictive dosimetry to be feasible within a small, highly select data set. Prospective validation trials on tumor predictive dosimetry are now needed, using 90 Y PET-based absorbed doses as a reference. Our tumor dose-response results are only orientating and should be further validated by greater patient numbers and by using more adequate tumor response end points. It should also be noted that our doseresponse results for both target and non-target tissue may not necessarily be valid for 90 Y glass microspheres due to different physical characteristics.
We did not perform absorbed dose quantification of the non-tumorous liver or lungs as these are regions of much lower 90 Y radioconcentration which may require further research and technical considerations on its The specific aim of our tumor analysis was to evaluate the best possible performance of tumor predictive dosimetry planned by 99m Tc MAA SPECT/CT. We are therefore limited by our study design to restrict our discussion only to the tumor aspect of predictive dosimetry; our study cannot draw conclusions on predictive dosimetry applied to non-tumorous liver or lungs. To this end, we have shown in our highly select tumor data set that the intended tumor mean doses by 99m Tc MAA SPECT/ CT predictive dosimetry correlated well with postradioembolization doses by 90 Y PET. From a clinical perspective, this means that if tumor predictive dosimetry had been applied to a technically successful 90 Y radioembolization under near-ideal dosimetric conditions, then the intended tumor mean doses may be assumed valid and retrospective tumor dose quantification is usually unnecessary, unless for research or quality assurance.
In less ideal dosimetric conditions, tumor predictive dosimetry may be of variable accuracy, and retrospective tumor dose quantification by 90 Y PET may be an option at the discretion of the nuclear medicine physician, e.g., MIRD-based predictive dosimetry applied to massive tumors with large heterogeneous areas of relative hypovascularity, where its assumption of a uniform activity biodistribution risks dosimetric uncertainty; or MIRDbased tumor predictive dosimetry applied to intended radiomicrosphere lobectomy or segmentectomy, where potential vascular stasis and reflux introduces dosimetric uncertainty. However, in technically unsuccessful 90 Y radioembolization, we feel that retrospective tumor dose quantification by 90 Y PET may be routinely indicated because the intended tumor doses by predictive dosimetry may have become invalid. Furthermore, non-target activity may also be present. In such situations, the prognosis remains uncertain unless retrospective dose quantification is performed within appropriate regions of interest.
90 Y PET/CT is but one component near the end of the entire planning-therapy continuum.
90 Y PET/CT is a descriptive modality to assess post-implantation microsphere biodistribution, where all inadvertent or adverse findings have already irreversibly occurred. To the nuclear medicine physician, the component of the planningtherapy continuum with the greatest prognostic impact, but also more complex, is predictive dosimetry. In principle, 90 Y radioembolization planned by predictive dosimetry is not subject to prognostic uncertainties experienced by semi-empirical 90 Y activity prescription, a common practice within the medical oncology paradigm. In the modern era of personalized medicine, predictive dosimetry planned by modern tomographical techniques give nuclear medicine physicians unprecedented insight into the achievable outcomes for every 90 Y radioembolization [6] . Technical success does not necessarily imply clinical success: the former is a qualitative assessment of microsphere biodistribution; the latter is a quantitative function of dose-response radiobiology. While interventional radiologists do their utmost to achieve technical success, it is the responsibility of the nuclear medicine physician to ensure that their efforts can be translated into clinical success by the rigorous application of predictive dosimetry.
Conclusions
Qualitative and quantitative post-radioembolization 90 Y PET/CT are two sides of the same coin and must be interpreted in the context of each other, never in isolation. Tumor and non-target tissue absorbed dose quantification by 90 Y PET is accurate and yields radiobiologically meaningful dose-response information to guide adjuvant or mitigative action. 
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